Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia

Part of Leukemia

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic myelomonocytic leukemia

61 trials tracked for Chronic myelomonocytic leukemia: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 120 citations.

61Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 5 Phase 2 43 Phase 1 6 Other / NA 7
  1. Phase 3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Completed · 120 cited
  2. Phase 3 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML Completed · 82 cited
  3. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  4. Phase 3 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed
  5. Phase 3 Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Completed
  6. Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed
Show 44 more trials
  1. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  2. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  3. Phase 2 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia Completed
  4. Phase 2 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed
  5. Phase 2 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed
  6. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  7. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  8. Phase 2 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Completed
  9. Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Completed
  10. Phase 2 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed
  11. Phase 2 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed
  12. Phase 2 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  13. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  14. Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Completed
  15. Phase 2 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed
  16. Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Completed
  17. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Completed
  18. Phase 2 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed
  19. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  20. Phase 2 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed
  21. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  22. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  23. Phase 2 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant Completed
  24. Phase 2 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed
  25. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  26. Phase 2 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed
  27. Phase 2 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Completed
  28. Phase 2 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome Completed
  29. Phase 2 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Completed
  30. Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Completed
  31. Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Completed
  32. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  33. Phase 2 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Completed
  34. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  35. Phase 2 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  36. Phase 2 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Completed
  37. Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed
  38. Phase 2 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  39. Phase 2 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed
  40. Phase 2 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Completed
  41. Phase 2 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Completed
  42. Phase 2 Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed
  43. Phase 1 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Completed
  44. Phase 1 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
Allergy & Immunology Sys. Review
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Frontiers May 14, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
Hematology
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Frontiers Apr 1, 2026

Research across Leukemia

Related studies from across the Leukemia family.

AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
Oncology Meta-analysis
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Jun 12, 2026
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Hematology RCT
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Jun 8, 2026
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
Drug Pipeline Meta-analysis
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
medRxiv Jun 4, 2026
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Oncology Sys. Review
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
Frontiers Jun 4, 2026
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Hematology Meta-analysis
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Jun 1, 2026
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Allergy & Immunology Sys. Review
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Frontiers Jun 1, 2026
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Diabetes & Endocrinology Sys. Review
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Frontiers Jun 1, 2026
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
Hematology FDA Approval
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
FDA May 30, 2026
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
Hematology Meta-analysis
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Frontiers May 29, 2026
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations
Drug Pipeline Sys. Review
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations Scientists examine how sugar metabolism affects acute myeloid leukemia cells
This narrative review examines glycolytic enzymes and glycolytic metabolism within acute myeloid leukemia (AML) cells. The authors synthesiz…
This review looks at how glycolytic enzymes and metabolism impact acute myeloid leukemia cells, offering new insights into this serious bloo…
Frontiers May 25, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Hematology Sys. Review
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
Frontiers May 15, 2026

Questions about Chronic myelomonocytic leukemia

Can ruxolitinib help CMML patients who also have connective tissue disease?

A specific case report shows that combining azacytidine with ruxolitinib helped a patient with connective tissue disease, CMML, and myelofibrosis by reducing fever, correcting high monocyte counts, and improving anemia.

Full answer →
What happens if a CMML patient is first diagnosed with ITP?

CMML can be misdiagnosed as ITP when thrombocytopenia is the first symptom; immunosuppressive therapy may temporarily raise platelets, but the underlying CMML progresses. Decitabine can stabilize the condition.

Full answer →